Clinical Trial Comment Sends Paradigm Share Price Plummeting

Paradigm Biopharmaceuticals [ASX:PAR] wiped 52.86% off its share price today, after a less-than-stellar update from one of its clinical trials.

What happened?

The company, which was researching potential hay fever treatments, was told the trial had not met crucial objectives. A poor result, which was reflected in the company’s share price.

Paradigm CEO Paul Rennie, while disappointed, is confident the company can move forward:

‘In the coming weeks, Paradigm will receive the final report and the drug master file, allowing for an independent expert to conduct an in-depth investigation, in order to determine the next steps for our allergic rhinitis program.’

In the short term, however, it is a substantial stumbling block for the company.

Where to from here for ASX:PAR?

Paradigm has two other clinical trials being conducted at the moment, both due in the third quarter, as well as a peer-review publication detailing the effect of pentosane polysulfate sodium (PPS) in osteoarthritis, focusing on bone marrow lesions (bone marrow edema).

Paradigm will no doubt be looking for positive signs from each of these milestones in the months ahead. Whether today’s failure can be salvaged into a positive outlook will be a priority for the company moving forward.

Regards,

Ryan Clarkson-Ledward,
Junior Analyst, Money Morning

PS: If you want to learn about five companies in danger of crashing like Paradigm, you’ll want to read Vern Gowdie’s free report, ‘Five Fatal Stocks You Must Sell Now’.

In it, Vern reveals five household names that aren’t safe with your money, and the US bubble that will hit these stocks hard.

To secure your finances, get your copy of Vern’s report right here

Free report reveals:

Your Best Chance to Bank 1000% Returns in Under a Year

Analysts ignore them. 90% of hedge funds won’t touch them. And it’s a miracle if you find them mentioned in the press. Yet these ‘off-the-grid’ stocks have been handing private investors like you 300%, 600% even 1000% gains for the last 50 years. In this special investor report you’ll learn how you could quickly lock-on to some of the best small-cap stocks in the market today.

Download this free report right now and discover:

• The Quick and Four Step Guide to Small-Cap Success: Sam believes the BEST way to get wealthy from stocks fast is to buy good small companies BEFORE the mainstream catches wind. This four step plan will show you how to find quality small-cap stocks that could potentially double or triple your money in a matter of months.
• How to Potentially Make More Money in One Year than Your Super Fund Does in 30: The mainstream don’t touch small-caps. That means you’ve got the whole playing field to yourself. As you’ll learn, a few well-timed punts here could reward you with the kind of returns in a single year buy-and-hold investors wait decades for.
• Why Warren Buffett Wishes He Had LESS Money to Invest: Don’t have a lot of money to invest right now? Not a problem. Learn the reason the world’s most successful investor wishes he had less money to throw in the markets (and why this gives YOU an advantage to grab huge returns in a short amount of time).

To download your copy of ‘The ‘At-Home’ Investors Guide to Profiting from Australian Small-Caps’ take out your free subscription to Money Morning. Simply enter your email address in the box below and click ‘Subscribe Now’.

We will collect and handle your personal information in accordance with our Privacy Policy. You can cancel your subscription at any time.

• Bio
• Latest Posts

Ryan Clarkson-Ledward

Latest posts by Ryan Clarkson-Ledward (see all)

• Clinical Trial Comment Sends Paradigm Share Price Plummeting - 16/06/2017
• NZ Milk Company a2 Upgrades Outlook, Share Price Rises - 16/06/2017
• Capitol Health Sell Off Sends Share Price Up - 14/06/2017
• Novatti Group Share Price Surged 30% in a day, why? - 13/06/2017
• Middle Island Resources ASX:MDI Finds Pay Dirt - 07/06/2017